Clinical Trial Update: A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of D4064A for recurrent/persistent epithelial ovarian, primary peritoneal, or fallopian tube cancer is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• D4064A

Snippet

Sponsor: Genentech, Inc. | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Status: SUSPENDED